Nyxoah SA (NASDAQ:NYXH) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Consensus rating: "Moderate Buy" — Five analysts cover Nyxoah with one sell and four buys, and the average 12‑month price target is $11.25.
• Shares opened at $2.82 (52‑week range $2.77–$8.64) and the company has a market cap of about $109.3M, but reported a quarterly EPS of ‑$0.68 (missing estimates) and extremely negative profitability metrics with analysts forecasting ~‑1.91 EPS for the year.
• Analyst and institutional activity is mixed: Weiss Ratings reiterated a sell (D‑), Cantor Fitzgerald and Stifel maintain buy/overweight views with $10–$11 targets, while several funds (e.g., Heights Capital, Deutsche Bank, Citadel) have recently initiated or increased stakes.

Nyxoah SA (NASDAQ:NYXH - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $11.25.

NYXH has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nyxoah in a research report on Monday, December 29th. Cantor Fitzgerald reissued an "overweight" rating and issued a $11.00 target price on shares of Nyxoah in a report on Monday, March 23rd. Finally, Stifel Nicolaus decreased their target price on shares of Nyxoah from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, March 20th.

Nyxoah Price Performance

Shares of Nyxoah stock opened at $2.82 on Monday. Nyxoah has a one year low of $2.77 and a one year high of $8.64. The stock's fifty day moving average is $4.13 and its 200 day moving average is $4.73. The stock has a market cap of $109.30 million, a P/E ratio of -1.05 and a beta of 1.56. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.16 and a current ratio of 1.25.

Nyxoah (NASDAQ:NYXH - Get Free Report) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.03). The company had revenue of $6.62 million for the quarter, compared to the consensus estimate of $5.70 million. Nyxoah had a negative net margin of 884.69% and a negative return on equity of 139.18%. Sell-side analysts anticipate that Nyxoah will post -1.91 earnings per share for the current year.

Institutional Trading of Nyxoah

Several institutional investors and hedge funds have recently modified their holdings of the company. Heights Capital Management Inc. bought a new stake in shares of Nyxoah during the fourth quarter valued at approximately $3,575,000. Deutsche Bank AG boosted its position in shares of Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company's stock worth $161,000 after acquiring an additional 10,000 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Nyxoah during the third quarter worth $98,000. Bank of America Corp DE grew its stake in Nyxoah by 152.7% during the third quarter. Bank of America Corp DE now owns 19,878 shares of the company's stock valued at $91,000 after acquiring an additional 12,012 shares in the last quarter. Finally, Raymond James Financial Inc. grew its stake in Nyxoah by 35.6% during the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company's stock valued at $59,000 after acquiring an additional 3,353 shares in the last quarter.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company's primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.